NICE recommends Tafinlar as a treatment for Metastatic Melanoma patients with BRAF V600 mutation- GSK
The National Institute for Health and Care Excellence (NICE) has recommended the use of Tafinlar (dabrafenib) from GSK for the treatment of Melanoma which has spread or cannot be completely removed by surgery and tests positive for the BRAF V600 mutation, which is linked to 50% of aggressive forms of the disease.
NICE has fast-tracked its recommendation for Tafinlar to the final draft stage in order to speed up access to the treatment. The recommendation is conditional on GSK supplying the drug to the NHS at an undisclosed discount to the list price. This drug will soon be transferred to Novartis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins